

Emergent BioSolutions Inc.
Form 8-K
June 07, 2012

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): June 1, 2012

Emergent BioSolutions Inc.
(Exact Name of Registrant as Specified in Charter)

| | | |
|---|--|--|
| Delaware (State or Other Jurisdiction of Incorporation) | 001-33137 (Commission File Number) | 14-1902018 (IRS Employer Identification No.) |
|---|--|--|

| | |
|---|---------------------|
| 2273 Research Boulevard, Suite 400, Rockville, Maryland (Address of Principal Executive Offices) | 20850 (Zip Code) |
|---|---------------------|

Registrant's telephone number, including area code: (301) 795-1800

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.01. Entry into a Material Definitive Agreement.

Biomedical Advanced Research and Development Authority Contract Modification

On June 1, 2012, Emergent BioDefense Operations Lansing LLC (“EBOL”), a wholly-owned subsidiary of Emergent BioSolutions Inc. (“Company”), entered into a contract modification with the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services to conduct a non-interference study to be used to support Post-Exposure Prophylaxis (“PEP”) indication for BioThrax® (“Anthrax Vaccine Adsorbed”). The modification requires EBOL to conduct the study, provides the Company with up to \$8.4 million in additional funding, extends the base period of performance of the contract from September 25, 2007 through March 31, 2016, and modifies the Milestone Table and Deliverables to incorporate the new study and extended base period of performance.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 7, 2012

EMERGENT BIOSOLUTIONS INC.

By:/s/Jay G. Reilly

Jay G. Reilly

General Counsel
